Patents by Inventor Megumi Mathison

Megumi Mathison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12031135
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: July 9, 2024
    Assignee: Baylor College of Medicine
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Publication number: 20220348921
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 3, 2022
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Patent number: 11421229
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 23, 2022
    Assignee: Baylor College of Medicine
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Publication number: 20220143142
    Abstract: Embodiments of the disclosure provide methods and compositions related to improving cardiomyocyte production by exposing starting cells to ETV2 and/or VEGF. The starting cells in specific embodiments are fibroblasts and/or endothelial cells, and following exposure to ETV2 and/or VEGF the resultant cells are exposed to one or more cardiomyocyte transdifferentiation factors, such as GATA4, myocyte enhancer factor-2c (Mef2c), T-box transcription factor 5 (TBX5), or a combination thereof. The produced cardiomyocytes are provided to individuals in need thereof, in particular embodiments.
    Type: Application
    Filed: March 17, 2020
    Publication date: May 12, 2022
    Inventors: Megumi Mathison, Todd Rosengart, Vivek P. Singh, Deepthi Sanagasetti, Jaya Pratap Pinnamaneni, Jianchang Yang
  • Publication number: 20220088143
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: December 9, 2021
    Publication date: March 24, 2022
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • Publication number: 20190358297
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • Patent number: 10383916
    Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 20, 2019
    Assignees: CORNELL UNIVERSITY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Ronald G. Crystal, Todd K. Rosengart, Robert Gersch, Megumi Mathison
  • Publication number: 20180066252
    Abstract: Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
    Type: Application
    Filed: February 19, 2016
    Publication date: March 8, 2018
    Inventors: Vivekkumar B. Patel, Hongran Wang, Vivek P. Singh, Erin Lynn Reineke, Megumi Mathison, Austin J. Cooney, Todd Rosengart
  • Patent number: 8790397
    Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: July 29, 2014
    Inventor: Megumi Mathison
  • Publication number: 20110265329
    Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.
    Type: Application
    Filed: July 13, 2011
    Publication date: November 3, 2011
    Applicant: Saint Joseph's Translation Research Institute, Inc .
    Inventor: Megumi Mathison
  • Patent number: 7998196
    Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: August 16, 2011
    Assignee: Saint Joseph's Translational Research Institute, Inc.
    Inventor: Megumi Mathison
  • Publication number: 20080262608
    Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.
    Type: Application
    Filed: April 21, 2008
    Publication date: October 23, 2008
    Applicant: SAINT JOSEPH'S RESEARCH INSTITUTE
    Inventor: Megumi MATHISON